MAPT and Alzheimer disease: To this end, progress towards early accurate diagnosis and effective treatments for AD has been mainly focused on the two hallmark pathologies with recent advances in developing assays for Aβ, tau and phosphorylated tau (pTau) species in cerebrospinal fluid (CSF) and plasma [5–7].